AzTrials
AzTrials

Condition

Hepatocellular Carcinoma Clinical Trials

Studies of hepatocellular carcinoma, matched by condition name and medical subject headings. Start with those open to enrolment.

4,053 registered studies

In numbers

Open to volunteers
961
Active
1,172
With results posted
417
All registered
4,053

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 961
  • Hepatocellular Carcinoma (HCC)

    Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 3
    • Surgery or procedure

    This study evaluates whether Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) improves overall survival compared with best supportive care (BSC).

    Trial name
    PULSAR-HCC (NCT07895732)
    Testing
    Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR)
    Where
    Canada
    Volunteers
    60 people
    Sponsor
    University Health Network, Toronto
    Can I take part? PULSAR-HCC
  • Hepatocellular Carcinoma Non-Resectable

    Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma

    • Not yet recruiting
    • Age: 18 years and older
    • Surgery or procedure

    Each year, approximately 1,000 patients in the Netherlands are diagnosed with liver cancer. When liver cancer can no longer be treated with surgery or thermal ablation, cure is no longer possible.

    Trial name
    OvercomeHCC (NCT07895342)
    Testing
    External beam radiotherapy, transarterial radioembolization
    Where
    Netherlands
    Volunteers
    16 people
    Sponsor
    Radboud University Medical Center
    Can I take part? OvercomeHCC
  • Hepatocellular Carcinoma, HCC

    Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

    • Recruiting
    • Age: 18 years and older
    • Phase 2
    • Surgery or procedure

    This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC).

    Trial name
    NCT04472767
    Testing
    Nivolumab, Ipilimumab, Cabozantinib
    Where
    United States
    Volunteers
    35 people
    Sponsor
    University of California, Irvine
    Can I take part? NCT04472767
  • Recurrent or Metastatic Solid Tumors

    A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

    • Recruiting
    • Age: 18 years and older
    • Phase 1/2

    This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…

    Trial name
    NCT06330064
    Testing
    Ifinatamab deruxtecan
    Where
    120 sites in United States, Argentina and 16 more
    Volunteers
    680 people
    Sponsor
    Daiichi Sankyo
    Can I take part? NCT06330064
  • Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma

    Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

    • Recruiting
    • Age: 18 years and older
    • Phase 1/2
    • Surgery or procedure

    This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started…

    Conditions
    Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
    Trial name
    NCT06811116
    Testing
    Biospecimen Collection, Cabozantinib S-malate, Imaging Procedure
    Where
    4 sites in United States
    Volunteers
    92 people
    Sponsor
    National Cancer Institute (NCI)
    Can I take part? NCT06811116
  • Hepatocellular Carcinoma

    Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.

    • Recruiting
    • Age: 18 to 70 years
    • Phase 1

    Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection.

    Trial name
    KARCHER-1 (NCT04587739)
    Testing
    Surgery with Neoadjuvant stereotactic body radiation therapy
    Where
    France
    Volunteers
    30 people
    Sponsor
    University Hospital, Lille
    Can I take part? KARCHER-1
  • HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)

    ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort

    • Recruiting
    • Age: 18 years and older
    • Observational study

    This Vietnam-based observational study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor…

    Conditions
    HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer
    Trial name
    NCT07808164
    Testing
    IHC analysis for ENPP1, cGAS, and FAP expression
    Where
    2 sites in Vietnam
    Volunteers
    162 people
    Sponsor
    Tam Anh Research Institute
    Can I take part? NCT07808164
  • Advanced Hepatocellular Carcinoma, Cirrhosis

    Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

    • Recruiting
    • Age: 18 years and older
    • Phase 1/2
    • Surgery or procedure

    This phase Ib/II trial tests the safety, side effects, and best dose of zanzalintinib and how well it works in treating patients with hepatocellular (liver) cancer that may have spread from where it first started to nearby…

    Conditions
    Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
    Trial name
    NCT07042919
    Testing
    Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
    Where
    United States
    Volunteers
    59 people
    Sponsor
    Devalingam Mahalingam
    Can I take part? NCT07042919
  • Advanced Hepatocellular Carcinoma, Lung Cancer

    Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

    • Recruiting
    • Age: 18 to 80 years
    • Observational study
    • Surgery or procedure

    Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical…

    Conditions
    Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
    Trial name
    NCT06644430
    Testing
    Ablation, system therapy
    Where
    China
    Volunteers
    470 people
    Sponsor
    Sun Yat-sen University
    Can I take part? NCT06644430
  • Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC)

    A Phase 1 Study of the Safety and Tolerability of CTX-10726

    • Recruiting
    • Age: 18 years and older
    • Phase 1

    This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies.

    Conditions
    Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
    Trial name
    NCT07419841
    Testing
    CTX-10726
    Where
    8 sites in United States
    Volunteers
    70 people
    Sponsor
    Compass Therapeutics
    Can I take part? NCT07419841

Completed, with results posted

All 297
  • Hepatocellular Cancer

    Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

    • Completed
    • Age: 18 to 100 years
    • Phase 2
    • Results posted

    The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with…

    Trial name
    NCT03037437
    Testing
    Sorafenib (SOR), Hydroxychloroquine (HCQ)
    Where
    United States
    Volunteers
    37 people
    Sponsor
    The University of Texas Health Science Center at San Antonio
    Can I take part? NCT03037437
  • Carcinoma, Hepatocellular

    A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

    • Completed
    • Age: 18 years and older
    • Phase 1/2
    • Results posted

    The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular…

    Trial name
    RELATIVITY-106 (NCT05337137)
    Testing
    Relatlimab, Nivolumab, Bevacizumab
    Where
    61 sites in United States, Australia and 13 more
    Volunteers
    82 people
    Sponsor
    Bristol-Myers Squibb
  • Gastrointestinal Cancers, Cholangiocarcinoma

    Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

    • Completed
    • Age: 18 years and older
    • Phase 2
    • Results posted

    Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma…

    Conditions
    Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer
    Trial name
    18F-FAPI-74 GI (NCT05641896)
    Testing
    [18F]FAPI-74 PET/CT
    Where
    6 sites in United States
    Volunteers
    112 people
    Sponsor
    SOFIE
  • Carcinoma, Hepatocellular

    ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

    • Completed
    • Age: 18 years and older
    • Phase 1/2
    • Results posted

    Open-label, uncontrolled, Phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma

    Trial name
    NCT03897543
    Testing
    ABX196
    Where
    2 sites in United States
    Volunteers
    10 people
    Sponsor
    Abivax S.A.
    Can I take part? NCT03897543
  • Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8

    68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

    • Completed
    • Age: 18 years and older
    • Phase 2
    • Surgery or procedure
    • Results posted

    This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the…

    Conditions
    Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
    Trial name
    NCT05176223
    Testing
    Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
    Where
    United States
    Volunteers
    26 people
    Sponsor
    Mayo Clinic
    Can I take part? NCT05176223

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in